drugset / Trial / NCT07187752
Identification of HER2-Positive Breast Cancer Molecular Characterization and Subtypes
NaSingle-groupOpen-labelTreatment
Summary
This study will evaluate the safety and efficacy of neoadjuvant trastuzumab, pertuzumab and chemotherapy chosen by the investigators and identify the molecular characterization and subtypes in human epidermal growth factor receptor 2 (HER2)-positive breast cancer.
Timeline
- Start
- 2025-09-30
- Primary completion
- 2026-12-31
- Completion
- 2027-06-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Pertuzumab | Monoclonal antibody | 420 mg | — |
| Subject | Trastuzumab | Monoclonal antibody | 6 mg/kg | — |